Non-Small Cell Lung Cancer Coverage from Every Angle
Editor:
David S. Ettinger, MD, FACP, FCCP
Advertisement
Advertisement

Videos

Stephanie T. Schmidt, PhD, on Neoadjuvant Chemotherapy and Immune-Based Treatments in NSCLC

C. Jillian Tsai, MD, PhD, on Using Stereotactic Body Radiotherapy to Reduce Oligoprogression in Advanced Lung Cancer

Benjamin Besse, MD, PhD: Expert Insights Into a Neoepitope Vaccine for NSCLC

Nasser K. Altorki, MD: Expert Perspective on the IMpower010 Study of Atezolizumab for NSCLC

Robin Cornelissen, MD, PhD, on ZENITH20-4: Use of Poziotinib Under Study in HER2 Exon 20–Mutated NSCLC

Martin Reck, MD, PhD, on Dual Immunotherapy Plus Chemotherapy: A Better Way to Treat NSCLC Than Chemotherapy Alone?

Vamsidhar Velcheti, MD, on CodeBreaK 100: Update on Use of Sotorasib in NSCLC

Heather A. Wakelee, MD, on Clinical Implications of Treating NSCLC With Atezolizumab

Martin Reck, MD, PhD, on Monotherapy vs Combination Treatment for High PD-L1–Expressing NSCLC: Expert Perspective

Silvia Novello, MD, PhD, on NSCLC Treatment Guided by Pharmacogenomics

Benjamin Besse, MD, PhD, on Clinical Tips for Prescribing Atezolizumab as Neoadjuvant Therapy for Resectable NSCLC

David S. Hong, MD, on a Novel First-in-Class Agent Under Study in Non–Small Cell Lung Cancer

Masahiro Tsuboi, MD, on Osimertinib as Adjuvant Treatment in EGFR-Mutated NSCLC

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Suresh S. Ramalingam, MD, on Clinical Implications of Using Nivolumab Plus Ipilimumab in First-Line NSCLC

Julia K. Rotow, MD, on Concurrent Osimertinib Plus Gefitinib in First-Line Treatment of NSCLC

Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

Edward B. Garon, MD, on Capmatinib in METex14-Mutated Advanced NSCLC: Expert Perspective

Solange Peters, MD, PhD, on Managing Toxicities of Checkpoint Inhibitors and Chemotherapy Regimens in NSCLC

Cristina Merkhofer, MD, MHS, on NSCLC: Monitoring Patients in Lieu of Clinical Trials

Andreas Rimner, MD, on Consolidation Therapy With Durvalumab in Later-Stage Lung Cancer

Bernardo H.L. Goulart, MD: How Do You Tell Patients That Money Matters in NSCLC Treatment?

Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Treatment Update on BLU-667

Suresh S. Ramalingam, MD, on Managing Pyrexia With Dabrafenib/Trametinib in Advanced NSCLC

David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Shirish M. Gadgeel, MD, on Advanced Non–Small Cell Lung Cancer: Integrating Chemotherapy and Immunotherapy

Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: Is There Still a Role for Chemotherapy?

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Predicting Survival Outcomes

Leora Horn, MD, on Managing the Adverse Events of Combination Therapies

Jessica S. Donington, MD, on Treating Early-Stage Thoracic Cancers

Nicolas Guibert, MD, PhD, on Non–Small Cell Lung Cancer: Clinical Implications of Using a New Algorithm to Predict Response to Immunotherapy

Edward B. Garon, MD, on Non–Small Cell Lung Cancer: Reducing the Frequency of Nivolumab Dosing

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy Perspectives

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Leora Horn, MD, on NSCLC: The Path Forward for ALK Inhibitors and Immunotherapy

Mark G. Kris, MD, on NSCLC: Juggling Sequence and Agent Choices in Lung Cancer

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Karen Reckamp, MD, on Metastatic NSCLC: Targeted Treatment Updates

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient’s Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

Roy S. Herbst, MD, PhD, on Lung Cancer: Update on Immunotherapy

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Martin Reck, MD, PhD, on Selecting Immunotherapy

Kathrin Milbury, PhD, on Patients With Lung Cancer: Benefits of Yoga

Luis G. Paz-Ares, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

Silvia Formenti, MD, on Combining Immunotherapy and Radiation Therapy

Clemens Grassberger, PhD, on NSCLC: Therapy Sequencing Criteria

Mariano Provencio, MD, PhD, on NSCLC: Results From the NADIM and NORA Trials

Martin Reck, MD, PhD, on NSCLC: Results From Three Key Trials

Virginie Westeel, MD, PhD, on NSCLC: Results From the IFCT-0302 Trial

Tony Mok, MD, on Oncogene-Addicted NSCLC: Expert Perspective on the Challenges

Alice Tsang Shaw, MD, PhD, and Tony Mok, MD: Results From the ARCHER 1050 Trial

Ramaswamy Govindan, MD, and Yi-Long Wu, MD: Results From the CTONG ADJUVANT Trial

Ramaswamy Govindan, MD, and Jaafar Bennouna, MD: Results From the AvaALL Trial

David S. Ettinger, MD, and Matthew A. Gubens, MD: Immunotherapies for Lung Cancer

Gregory J. Riely, MD, PhD, and David S. Ettinger, MD: The What, When, and How of Biomarker Testing

Wallace Akerley, MD, and David S. Ettinger, MD: Biomarker-Based Treatment Selection

Stephanie Andrews, MS, ANP-BC, on Managing Toxicities of Immunotherapies

David S. Ettinger, MD, on The Importance of the NCCN Guidelines in Lung Cancer

Daniel R. Gomez, MD, on Immunotherapy in Lung Cancer and the Value Proposition

Walter J. Curran, MD, on Stage III NSCLC

Benjamin Movsas, MD, and Quynh Nguyen, MD, on Quality of Life and Palliative Care in Lung Cancer

Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

Virginie Westeel, MD, PhD, on Managing Immune-Related Adverse Events Associated With Checkpoint Inhibitor Therapy

The JNCCN Spotlight

Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.